Yahoo Finanzas The Medical University of Vienna's Paediatric Heart Centre Purchases Ventripoint's AI-Powered Heart Imaging System
Toronto, Ontario --News Direct-- Ventripoint Diagnostics Ltd.
Toronto, Ontario – TheNewswire – February 1, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF), a leader in using AI for heart imaging, is pleased to announce The Paediatric Heart Centre at the Medical University of Vienna has chosen to adopt the VMS+ as its cardiac diagnostic tool.
The Paediatric Cardiology Department is part of the Children’s Heart Centre Vienna and is the oldest pediatric cardiology department in Austria. The core unit is the Department of Paediatric Cardiology, located at the University Hospital for Children and Adolescent Medicine.
“We are very excited to be partnering with this world-renowned hospital to bring our technology to the doctors and patients at The Paediatric Heart Centre cardiac-care programs,” said Dr. Alvira Macanovic, Ventripoint’s CEO and President. “This continues our strategy of placing our VMS+ diagnostic units, which offer a cost-effective alternative to cardiac MRIs, in leading hospitals around the world.”
Using the VMS+, caregivers at the Paediatric Cardiology Department can use ultrasound images to create detailed heart scans in minutes at a fraction of the costs of MRIs. The Paediatric Cardiology Department provides world-renowned care for children with heart disease and is widely recognized for having industry leaders as its main care providers.
Ventripoint is committed to improving patient care through innovative technologies like the VMS+ and will continue to bring our AI-powered diagnostic technologies to healthcare professionals and institutions.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
View source version on newsdirect.com: https://newsdirect.com/news/the-medical-university-of-viennas-paediatric-heart-centre-purchases-ventripoints-ai-powered-heart-imaging-system-208324025
